Proactiveinvestors United Kingdom Humanigen, Inc. https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Humanigen, Inc. RSS feed en Wed, 29 Jan 2020 20:36:00 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Humanigen appoints Korn Ferry senior exec Cheryl Buxton to board https://www.proactiveinvestors.co.uk/companies/news/909277/humanigen-appoints-korn-ferry-senior-exec-cheryl-buxton-to-board-909277.html Mon, 16 Dec 2019 14:59:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/909277/humanigen-appoints-korn-ferry-senior-exec-cheryl-buxton-to-board-909277.html Humanigen wins hematological society award for leukemia treatment presentation https://www.proactiveinvestors.co.uk/companies/news/908986/humanigen-wins-hematological-society-award-for-leukemia-treatment-presentation-908986.html Wed, 11 Dec 2019 14:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/908986/humanigen-wins-hematological-society-award-for-leukemia-treatment-presentation-908986.html Humanigen to present abstracts highlighting its glioblastoma treatments at industry conference https://www.proactiveinvestors.co.uk/companies/news/906885/humanigen-to-present-abstracts-highlighting-its-glioblastoma-treatments-at-industry-conference-906885.html Tue, 12 Nov 2019 21:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/906885/humanigen-to-present-abstracts-highlighting-its-glioblastoma-treatments-at-industry-conference-906885.html Humanigen’s abstracts on lenzilumab to be presented at the American Society of Hematology https://www.proactiveinvestors.co.uk/companies/news/906465/humanigens-abstracts-on-lenzilumab-to-be-presented-at-the-american-society-of-hematology-906465.html Wed, 06 Nov 2019 19:05:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/906465/humanigens-abstracts-on-lenzilumab-to-be-presented-at-the-american-society-of-hematology-906465.html Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite https://www.proactiveinvestors.co.uk/companies/news/905471/humanigen-updates-on-its-clinical-collaboration-with-gilead-sciences-subsidiary-kite-905471.html Wed, 23 Oct 2019 18:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905471/humanigen-updates-on-its-clinical-collaboration-with-gilead-sciences-subsidiary-kite-905471.html Humanigen contemplating raising funds by conducting a broadly syndicated rights offering https://www.proactiveinvestors.co.uk/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Tue, 15 Oct 2019 13:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article https://www.proactiveinvestors.co.uk/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Tue, 08 Oct 2019 14:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich https://www.proactiveinvestors.co.uk/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html Mon, 22 Jul 2019 20:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients https://www.proactiveinvestors.co.uk/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html Mon, 22 Jul 2019 18:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html Humanigen teams up with Kite to treat a type of lymphoma cancer https://www.proactiveinvestors.co.uk/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html Mon, 10 Jun 2019 18:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html Humanigen and Gilead's Kite to work on study to evaluate Yescarta with lenzilumab to treat a type of lymphoma https://www.proactiveinvestors.co.uk/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html Fri, 31 May 2019 14:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal https://www.proactiveinvestors.co.uk/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html Fri, 17 May 2019 14:11:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html Humanigen unveils promising results from Ifabotuzumab Phase I study at the American Association for Cancer Research's annual meeting https://www.proactiveinvestors.co.uk/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html Mon, 01 Apr 2019 08:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html Humanigen's new data show increase in mice survival with lenzilumab https://www.proactiveinvestors.co.uk/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html Thu, 28 Mar 2019 16:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html Humanigen presents new study showing lenzilumab's potential to fight tumors https://www.proactiveinvestors.co.uk/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html Fri, 22 Mar 2019 12:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html Humanigen CEO optimistic on drug candidate after pulling company from the brink https://www.proactiveinvestors.co.uk/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html Tue, 05 Mar 2019 19:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html Humanigen pins hopes on monoclonal antibody treatment of cancer therapy's side effects https://www.proactiveinvestors.co.uk/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html Mon, 04 Mar 2019 20:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference https://www.proactiveinvestors.co.uk/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html Mon, 25 Feb 2019 14:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal https://www.proactiveinvestors.co.uk/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html Fri, 15 Feb 2019 14:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html Humanigen has gleaned 'significant' interest from potential partners from its data presentation https://www.proactiveinvestors.co.uk/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html Mon, 11 Feb 2019 12:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html Humanigen new research shows encouraging results for cancer treatment using Car-T https://www.proactiveinvestors.co.uk/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html Wed, 05 Dec 2018 20:53:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer https://www.proactiveinvestors.co.uk/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html Sat, 09 Jun 2018 20:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html